How Healthy (For Investors) Are These Small Cap Health Care or Personal Car Stocks? AXXE, RCGP & TAUG

Small cap health care or personal care stocks Axxess Pharma Inc (OTCMKTS: AXXE), Radiant Creations Group Inc (OTCBB: RCGP) and Tauriga Sciences Inc (OTCMKTS: TAUG) have recently been attracting attention in various investment newsletters or in investor alerts. Some of the attention may have to do with paid promotions that two of these small caps have been the subject of. So how healthy are these three small cap health care or personal care orientated stocks? Here is a checkup:

Axxess Pharma Inc (OTCMKTS: AXXE) Has Been Busy Announcing Deals

Small cap Axxess Pharma Inc's wholly-owned Canadian Subsidiary, Axxess Pharma Canada Inc., is a specialty Health Care Products Company dedicated to improving health and quality of life by offering select medicines, nutritional supplements and over the counter remedies all across the Americas. On Friday, Axxess Pharma Inc fell 2.44% to $0.20 for a market cap of $8.01 million plus AXXE is down 92.4% over the past year and down 99.9% over the past five years according to Google Finance.

What's the Catch With Axxess Pharma Inc? According to various disclosures, transactions of $2.5k, $3k, $4k, $14k, $25k, $50k and $85k have or will occur to mention Axxess Pharma Inc in various investment newsletters plus the company has been busy announcing new deals. Last Wednesday, Axxess Pharma Inc announced it had signed term sheet from TCA Global Credit Masters Fund to secure a $4 million revolving line of credit which was expected to close within 14 days pending final due diligence. The press release stated the revolving line of credit would enable Axxess Pharma to "generate significant revenue in the near-term with high gross profit margins" plus the deal was expected to be the beginning of a long-term long-term partnership between the two companies. Last Monday, Axxess Pharma Inc also announced an exclusive agreement providing them the world-wide exclusive rights to develop, market and sell a line of pain relief and muscle recovery products, as well as develop and market a vitamins and minerals line under the TapouT brand name; while back in September, the company announced an agreement for the acquisition of the assets of Revive Bioscience Inc. - a leading Canadian OTC healthcare company. However, a quick look at both Google Finance and Yahoo! Finance reveals no financials for Axxess Pharma Inc – meaning its investor beware.

Radiant Creations Group Inc (OTCBB: RCGP) Is Launching Its Direct to Consumer Sales Model

Small cap Radiant Creations Group Inc says it has achieved exciting breakthroughs creating remarkable products in skin protection and hydration, anti-aging, liver health and weight balance by combining DNA technologies developed in the Western World and naturally acting traditional Chinese medicine ingredients believed to be never before used in western culture by any bioscience company. On Friday, Radiant Creations Group Inc fell 9.1% to $0.20 for a market cap of $6 million plus RCGP is up 53.85 over the past year and down 60% since November 2011 according to Google Finance.

What's the Catch With Radiant Creations Group Inc? According to various disclosures, no transactions have occurred to mention the Radiant Creations Group in various investment newsletters. Last Friday, Radiant Creations Group Inc announced the launch of its direct to consumer sales model by mid November 2013 with the company conservatively targeting about 100 units per day for the first 60 days and then ramping up to 150 sales per day by the end of the fiscal year ending February 28, 2014 for gross monthly revenues in excess of $300,000. Last Thursday, Radiant Creations Group Inc announced its second quarter financials for the period ending August 31, 2013, where initial revenue of $37,672 (the first revenue achieved following the change in control of the company) was reported along with a net loss of was $1,031,484 (which included $795,489 of one-time cost and accounting adjustments related to the asset purchase dated June 27, 2013). Not mentioned in the press release are the latest balance sheet figures from Yahoo! Finance which showed the company had $14k in cash to cover $1,746k in current liabilities and another $100k in long term debt at the end of August. So maybe investors should wait for those who now control Radiant Creations Group Inc to launch and ramp up operations.

Tauriga Sciences Inc (OTCMKTS: TAUG) Gets Closer to Producing Revenues…

Small cap Tauriga Sciences is a diversified company focused on generating profitable revenues through license agreements and the development of a proprietary technology platform in the nano-robotics space. On Friday, Tauriga Sciences fell 0.90% to $0.022 for a market cap of $6.10 million plus TAUG is down 91.5% over the past year and down 93.7% over the past five years according to Google Finance.

10 Best Cheap Stocks To Invest In Right Now

What's the Catch With Tauriga Sciences Inc? According to various disclosures, a transaction or transactions of $15k has or will occur to mention Tauriga Sciences in various investment newsletters. Tauriga Sciences was busy issuing four press releases last week with the last press release on Friday announcing the receipt of SPEC sheets covering the full suite of 100% Tree-Free Bamboo products pursuant to the exclusive license agreement signed between the company and Green Hygienics, Inc on June 1, 2013. With the SPEC sheets, Tauriga Sciences can provide potential customers with the requisite paperwork to complete purchase orders and eventually generate profitable revenues. Tauriga Sciences also announced earlier in the week that it had a comprehensive Strategic Alliance Agreement with Cincinnati, Ohio-based synthetic biology pioneer Bacterial Robotics, LLC to jointly develop a nuclear industry-specific Bacterial Robot (which are genetically enhanced bacteria that conduct specific functions and are applicable to therapeutics, wastewater and chemicals). Apparently, Bacterial Robotics intends to grant a 10-year, fully paid, worldwide exclusive license agreement to Tauriga Sciences for the Bacterial Robotics technology. However, a quick look at Tauriga Sciences' financials reveals no revenues; net losses of $2,451k (most recent reported quarter), $2,939k, $5,468k and $4,595k for the past four reported quarters; and $91k in cash to cover $1,595k in current liabilities at the end of last June. So perhaps investors should wai for those SPEC sheets to start generating some revenues.